FIRE Funds Income Target ETF FIRI 深 滬
等待開盤 10-09 09:30:00 美东时间
19.04
+0.030
+0.16%
華盛通- 最 高19.04
- 今 開18.98
- 成交量 210股
- 最 低 18.98
- 昨 收 19.01
- 總市值 123.76万
- 52周最高 19.04
- 市盈率 靜 --
- 換手率 0.32%
- 52周最低 17.6612
- 委 比 0.00%
- 總股本 6.50万
- 歷史最高 19.04
- 量 比 0.06
- 振 幅 0.32%
- 歷史最低 17.7417
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Elicio Therapeutics Announces Planned Initiation Of Investigator-Initiated Phase 1 Trial Of ELI-002 7P In Combination With Chemotherapy And Anti-PD1 Checkpoint Inhibitor In Borderline And Resectable PDAC
Study will evaluate ELI-002 7P in combination with chemotherapy and a checkpoint inhibitor ("CPI") in the neoadjuvant setting Trial is anticipated to begin enrolling in H1'2026 BOSTON, Sept. 29, 2025 (GLOBE
09-29 20:19
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 16, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's accelerated approval of two oncology treatments in August...
09-17 00:29
Oncolytics Biotech® Provides Update on GOBLET Study Progress and U.S. Site Expansion
SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announc...
09-16 19:00
Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Sept. 8, 2025 /PRNewswire/ -- USA News Group News Commentary – The FDA's unprecedented wave of Break...
09-08 21:30
Oncolytics Biotech Reports Pelareorep Boosts Survival In Colorectal Cancer Patients
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today highlighted clinical and translational data from three metastatic
09-08 19:10
AIM ImmunoTech Announces Company Update Including Mid-Year Report Of Ampligen In Combination With AstraZeneca's Imfinzi For Treatment Of Pancreatic Cancer Demonstrating Signs Of Both No Significant Toxicity And Superior PFS And OS.Company Also Bolstered Cash Position To Fund Operations For ~12 Months
Primary focus on pancreatic cancerMid-year report of Ampligen® (rintatolimod) in combination with AstraZeneca's Imfinzi® (durvalumab) for the treatment of pancreatic cancer demonstrates positive signs of both
08-04 21:06
Why Is Micro-Cap AIM ImmunoTech Stock Surging?
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients.
07-28 23:12
AIM ImmunoTech Announces Mid-Year Data From Phase 2 DURIPANC Trial Of Ampligen And AstraZeneca's Imfinzi In Metastatic Pancreatic Cancer Patients Post-FOLFIRINOX
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today reported positive data in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM's drug Ampligen® (rintatolimod) combined with
07-28 21:03
Xenetic Biosciences Announces First Patient Dosing In Exploratory Clinical Study Of Systemic DNase I In Combination With FOLFIRINOX For Advanced Or Metastatic Pancreatic Cancer
Investigator initiated exploratory clinical study being conducted in Israel pursuant to agreement with collaboration partner, PeriNessCompany evaluating systemic recombinant human DNase I (DNase I) in combination with
07-08 21:04
石药集团现涨近4% 同意授予Cipla在美销售伊立替康脂质体注射液独家许可
石药集团（01093）股价现涨3.68%，现报5.92港元，成交额2.03亿港元。 5月15日，石药集团发布公告，集团已与Cipla USA， Inc．（...
05-16 10:57
